Exact Sciences, Ultima Genomics ink supply agreement

2022 03 01 17 44 8262 Sequencing Virus 400

Exact Sciences and Ultima Genomics on Tuesday announced a long-term supply agreement by which Exact will obtain access to Ultima's next-generation sequencing (NGS) technologies.

Under the terms of the agreement, Ultima will provide access to its NGS products based on a new architecture designed to enable sequencing at lower cost, the firms said.

The companies also plan to develop one or more of Exact Sciences' cancer diagnostic tests using Ultima's sequencing technology.

In conjunction with the agreement, Exact Sciences became an investor in Ultima and joined its ongoing early access program for its high-throughput NGS instrument platform, the UG 100.

Page 1 of 50
Next Page